Sector News

Aerpio may hang the ‘for sale’ sign up, axes CEO after eye drug flop

October 21, 2019
Life sciences

In a classic plot line for biotechs, Aerpio Pharmaceuticals is seeking a “strategic review” for its business and assets after being hit by a trial failure for its leading med earlier this year.

The micro-cap biotech, with a market cap worth less than $20 million and trading in penny stock territory, said its board is “exploring the potential for an acquisition, company sale, merger, business combination, asset sale, in-license, out-license or other strategic transaction.” The chief executive, Michael Rogers, is also out the door.

Aerpio added that it “does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved,” so don’t expect any more press releases until some sort of deal is done—or not, as the case may be.

As well as looking to potentially sell off some or all of the company, Aerpio’s already slimming down, or, as it puts it, “streamlin(ing) operations in order to preserve its capital and cash resources.” It had under $50 million at last count in June.

Joseph Gardner, Ph.D., its current president (and founding CEO of Akebia Therapeutics), will now lead the dwindling C-suite team as Rogers alongside Chief Financial Officer Stephen Hoffman “have transitioned from their roles,” the biotech said in a brief update.

Back in May, shares in Aerpio were more than halved after the failure of its leading drug candidate.

The midstage test, known as the TIME-2b study, was assessing its drug AKB-9778 in diabetic retinopathy but missed its primary endpoint of a two-step reduction in its diabetic retinopathy severity score score when pitted against a dummy treatment.

The percentage of patients achieving this endpoint for the injectable AKB-9778 twice daily and placebo were 9.6% and 3.8%, respectively (p=0.270). Across all eyes, those achieving this endpoint was 8.6% and 2.7%, for AKB-9778 BID and placebo, respectively (p=0.158). That was a hard fail, and one that sent its shares into a free fall from which it has not recovered.

By Ben Adams

Source: Fierce Biotech

Related News

April 10, 2020

Covid-19 pandemic: knock-on effects for pharma supply chains

Life sciences

Covid-19 originated in China, which is where the clear majority of APIs for drugs are manufactured; China’s lockdown had a knock-on effect on its neighbour India, which relies on those […]

April 9, 2020

Which pharma companies are the most innovative?

Life sciences

The continued prosperity of a biopharma company is dependent on its ability to keep churning out breakthrough new drugs and turning them into commercial successes backed by a growing body […]

April 9, 2020

Global clinical trials take a major hit from pandemic

Life sciences

Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit. This is according to a new breakdown from Medidata (PDF), now owned […]